1. Algate, D. R., Augustin, J. and Atterson, P. R. (1995). General pharmacology of [2,2-dimethyl-6-(4-chlorophenyl)-7-phenyl-2,3-dihydro-1H-pyrrolizine-5-yl]-acetic acid in experimental animals, Arzneim.-Forsch./ Drug Research 45 (1), 2, 159–165.
2. Bias, P. (2000). Initial clinical studies with ML3000 in osteoarthritis. OARSI Satellite Symposium, Barcelona. October 5, 2000.
3. Bodiner, M. C. (1996). Effects of compound (ML3000) on carrageenan edema: measurements of edema volume and PGE2 and LTB4 in situ production. Merckle internal study report, manuscript in preparation.
4. Braquet, P. (1997). Effect of oral administration of 3 anti-in' ammatory compounds on prostaglandin (PGE2 ) and leukotriene (LTB4 ) production in the rat stomach. Merckle internal study report, manuscript in preparation.
5. Cook, E., Clifton, G. G., Vargas, R., et al. (1990). Pharmacokinetics, pharmacodynamics, and mini-mum effective clinical dose of intravenous nicardipine, Clin. Pharmacol. Ther. 47(6), 706–718.